Tirzepatide vs Retatrutide: More Weight Lost Is Not the Same as Better

The obesity drug conversation has moved fast. Single-hormone GLP-1 agonists gave way to tirzepatide, a dual agonist. Tirzepatide is now being compared against retatrutide, a triple agonist still working through its trial programme.

The framing in most coverage is a race, with retatrutide winning it. On the single axis of weight lost, that is true. On almost every other axis that determines whether a drug is a good idea for a specific person, tirzepatide is currently the better-evidenced choice — and the gap is not close.

What each drug actually does

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) targets two receptors:

  • GLP-1 — slows gastric emptying, signals satiety, increases glucose-dependent insulin secretion.
  • GIP — works alongside GLP-1 on appetite and on how fat is stored and handled.

Retatrutide adds a third: glucagon receptor agonism, which raises energy expenditure and drives hepatic fat breakdown. That third mechanism is why it moves both weight and liver fat so hard.

The weight-loss numbers, stated honestly

In SURMOUNT-1 (n = 2,539, 72 weeks, adults with obesity and without diabetes), mean weight reduction was 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, against 2.4% on placebo.

The commonly repeated "20–22%" is the top of that range, not the average experience. Dose matters.

Retatrutide's phase 2 obesity trial (n = 338, 48 weeks) reported 24.2% at the 12 mg dose, versus 2.1% on placebo. Phase 3 has since gone further: TRIUMPH-1 (n = 2,339, 80 weeks) reported 28.3% at 12 mg.

So the honest summary is that retatrutide produces more weight loss than tirzepatide, and does it faster. Any article claiming otherwise is arguing with the data.

The question worth asking is whether that is the metric that should decide the choice.

Why tirzepatide is still the stronger bet today

1. It has outcome data. Retatrutide does not.

Weight is a surrogate. What matters is whether people have fewer heart attacks, fewer hospitalisations, longer lives.

  • SUMMIT (n = 731, obesity-related HFpEF) reported a 38% relative reduction in the composite of cardiovascular death or worsening heart failure — HR 0.62 (95% CI 0.41–0.95, p = 0.026) — alongside improved symptom scores and six-minute walk distance.
  • SURPASS-CVOT enrolled 13,299 people with type 2 diabetes and established atherosclerotic disease and followed them for a median of roughly four years.

One caveat that most summaries drop: SURPASS-CVOT compared tirzepatide against dulaglutide, an active drug, not placebo. Tirzepatide met non-inferiority for major cardiovascular events (12.2% vs 13.1%) but did not demonstrate superiority (p = 0.09). It is not correct to say tirzepatide reduced cardiovascular events versus an active comparator. What the trial does establish is cardiovascular safety at scale, over years, in a high-risk population.

Retatrutide has no completed cardiovascular outcome trial.

2. Its effect on body composition has actually been measured

More on this below, but the short version: we know what tirzepatide does to fat versus lean mass because someone scanned people. For retatrutide, no equivalent published body-composition data exists.

If muscle preservation is your concern, that concern is answerable for one of these drugs and not the other.

3. It exists

Retatrutide is not approved. It is investigational, available inside trials, with a Biologics License Application planned for Q1 2027. Everything circulating outside a trial is unregulated.

Tirzepatide is approved, manufactured to pharmaceutical standard, and prescribed with monitoring.

The muscle-loss question, settled with actual measurements

The fear is that rapid weight loss strips skeletal muscle and leaves people frail. It is a reasonable thing to worry about. It has also now been directly measured.

A DXA substudy of SURMOUNT-1 scanned 160 participants at baseline and at week 72. Over 72 weeks on tirzepatide:

  • Fat mass fell 33.9%
  • Lean mass fell 10.9%

In isolation, an 11% drop in lean mass sounds like the alarm was justified. Then you look at the placebo group: fat mass −8.2%, lean mass −2.6%.

Run the ratio. In both groups, roughly 75% of the weight lost was fat and 25% was lean mass. The split was essentially identical whether people lost the weight on tirzepatide or without it.

That is the finding that matters. Tirzepatide does not preferentially strip muscle. Weight loss reduces lean mass — by any method, including diet alone — and this drug does it in the same proportion as everything else.

That ~25% figure is not new. Reviews of weight-loss composition have put fat-free mass at roughly 20–30% of total weight lost in people with obesity for years, a higher share in people who start lean.

Why losing some lean mass is not the same as getting weaker

A JAMA viewpoint by Conte, Hall and Klein addressed this directly. Their argument is that the reduction in fat-free mass is usually small relative to baseline, smaller in relative terms than the fat loss beside it, and accompanied by improved physical function. They state plainly that the concern that GLP-1-based medications cause frailty or sarcopenia is not supported by the data.

The mechanical logic holds up. A larger body needs more supporting tissue to move. When the load falls, some of that tissue is no longer required. Meanwhile fat stored inside muscle tissue clears and insulin sensitivity in muscle improves — less muscle, functioning better.

Where genuine caution belongs. Two subgroups in the SURMOUNT-1 substudy lost a lower proportion of fat: participants aged 65 and over, and those in the lowest weight-loss tertile. Older adults starting with less muscle to spare are a real clinical concern, not a manufactured one.

Protecting lean mass in practice

The evidence base here is thinner than people imply — there is no guideline written specifically for lean-mass preservation during GLP-1 or GIP therapy. The best available guidance comes from the general weight-loss literature.

  1. Protein. A review of muscle preservation during weight loss recommends 1.25–1.5× the RDA for sedentary people and more than 1.5× the RDA for those exercising. The RDA is 0.8 g/kg/day, so approximately 1.0–1.2 g/kg/day, higher if training. Widely circulated figures like "1.2–1.6 g/kg" are reasonable expert opinion but do not trace to a specific trial in this population. These drugs suppress appetite hard enough that hitting protein targets takes deliberate planning.
  1. Resistance training. Progressive resistance training alongside a hypocaloric diet attenuates muscle-mass loss. Cardio is good for other reasons; loading is the signal that retains tissue.
  1. Sleep and hydration. Foundational rather than optional.

The verdict

Retatrutide is the more powerful drug. Its phase 2 and phase 3 weight-loss results exceed tirzepatide's, its liver-fat data is remarkable, and it will likely change the field when it arrives.

But "loses more weight" and "is the better drug" are different claims, and only the first is currently supported. Tirzepatide has reported outcome trials, cardiovascular safety data in over 13,000 patients, a published measurement of what it does to fat versus lean mass, and regulatory approval. Retatrutide has none of those yet.

The muscle-loss narrative, meanwhile, does not survive contact with the DXA data. The proportion of weight lost as lean mass on tirzepatide is the same as losing it without a drug. Eat enough protein, lift something heavy, and the tissue you keep will be working better than it was.

Sources

  • Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
  • Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. doi:10.1111/dom.16275
  • Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437.
  • SURPASS-CVOT. N Engl J Med. 2025.
  • Conte C, Hall KD, Klein S. Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant? JAMA. 2024;332(1):9-10.
  • Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017;8(3):511-519.
  • Eli Lilly. TRIUMPH-1 topline results, May 2026; TRIUMPH-2 and TRIUMPH-3 topline results, July 2026.

Every claim above is drawn from the sources named. Where a finding is observational or from a phase 2 trial, it is described as such. This is general information, not medical advice.